Sei Investments Co. Increases Stock Position in Palvella Therapeutics, Inc. $PVLA

Sei Investments Co. boosted its holdings in Palvella Therapeutics, Inc. (NASDAQ:PVLA) by 42.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,663 shares of the company’s stock after acquiring an additional 4,944 shares during the quarter. Sei Investments Co.’s holdings in Palvella Therapeutics were worth $2,077,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. WCM Investment Management LLC bought a new position in shares of Palvella Therapeutics during the first quarter valued at $4,982,000. KBC Group NV bought a new stake in Palvella Therapeutics in the 1st quarter worth about $28,000. Swiss National Bank increased its holdings in Palvella Therapeutics by 36.6% in the 1st quarter. Swiss National Bank now owns 19,400 shares of the company’s stock worth $2,418,000 after buying an additional 5,200 shares in the last quarter. Jennison Associates LLC increased its holdings in Palvella Therapeutics by 65.3% in the 1st quarter. Jennison Associates LLC now owns 640,611 shares of the company’s stock worth $79,852,000 after buying an additional 253,128 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in Palvella Therapeutics by 10.9% in the 1st quarter. Bank of New York Mellon Corp now owns 18,041 shares of the company’s stock worth $2,249,000 after buying an additional 1,777 shares during the last quarter. Institutional investors own 40.11% of the company’s stock.

Insider Buying and Selling at Palvella Therapeutics

In related news, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $110.73, for a total value of $476,360.46. Following the transaction, the chief operating officer owned 2,154 shares of the company’s stock, valued at approximately $238,512.42. This trade represents a 66.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 17.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on PVLA shares. Canaccord Genuity Group set a $232.00 target price on shares of Palvella Therapeutics in a research note on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $270.00 price target on shares of Palvella Therapeutics in a research note on Wednesday, July 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a report on Monday, June 29th. Chardan Capital upgraded shares of Palvella Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Finally, Stephens restated an “overweight” rating and issued a $220.00 target price on shares of Palvella Therapeutics in a report on Thursday, May 21st. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $209.14.

Palvella Therapeutics Stock Performance

Palvella Therapeutics stock opened at $157.77 on Monday. Palvella Therapeutics, Inc. has a one year low of $38.95 and a one year high of $161.38. The stock has a fifty day moving average of $133.76 and a 200 day moving average of $120.16. The stock has a market cap of $2.27 billion, a PE ratio of -32.66 and a beta of -0.17.

Palvella Therapeutics (NASDAQ:PVLA) last announced its earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.35). As a group, sell-side analysts predict that Palvella Therapeutics, Inc. will post -6.36 EPS for the current fiscal year.

Palvella Therapeutics Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.